201 related articles for article (PubMed ID: 12172500)
1. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
2. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
[TBL] [Abstract][Full Text] [Related]
3. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
Pommier Y; Kohlhagen G; Bailly C; Waring M; Mazumder A; Kohn KW
Biochemistry; 1996 Oct; 35(41):13303-9. PubMed ID: 8873596
[TBL] [Abstract][Full Text] [Related]
4. A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.
Marco E; García-Nieto R; Mendieta J; Manzanares I; Cuevas C; Gago F
J Med Chem; 2002 Feb; 45(4):871-80. PubMed ID: 11831898
[TBL] [Abstract][Full Text] [Related]
5. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
7. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
9. [Ecteinascidin 743].
Lansiaux A; Bailly C
Bull Cancer; 1999 Feb; 86(2):139-41. PubMed ID: 10094523
[No Abstract] [Full Text] [Related]
10. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
11. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Aune GJ; Takagi K; Sordet O; Guirouilh-Barbat J; Antony S; Bohr VA; Pommier Y
Clin Cancer Res; 2008 Oct; 14(20):6449-55. PubMed ID: 18927284
[TBL] [Abstract][Full Text] [Related]
12. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
13. Ecteinascidin-743.
Held-Warmkessel J
Clin J Oncol Nurs; 2003; 7(3):313-9. PubMed ID: 12793338
[TBL] [Abstract][Full Text] [Related]
14. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
[TBL] [Abstract][Full Text] [Related]
15. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
16. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
Guirouilh-Barbat J; Antony S; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):2007-14. PubMed ID: 19584237
[TBL] [Abstract][Full Text] [Related]
17. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
Kanzaki A; Takebayashi Y; Ren XQ; Miyashita H; Mori S; Akiyama S; Pommier Y
Mol Cancer Ther; 2002 Dec; 1(14):1327-34. PubMed ID: 12516966
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
Wright BJ; Chan C; Danishefsky SJ
J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.
Takebayashi Y; Pourquier P; Zimonjic DB; Nakayama K; Emmert S; Ueda T; Urasaki Y; Kanzaki A; Akiyama SI; Popescu N; Kraemer KH; Pommier Y
Nat Med; 2001 Aug; 7(8):961-6. PubMed ID: 11479630
[TBL] [Abstract][Full Text] [Related]
20. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
